Hanx Biopharmaceuticals (Wuhan) Co., Ltd. Fundamental Analysis
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (3378.HK) shows weak financial fundamentals with a PE ratio of 82.62, profit margin of 2.99%, and ROE of 13.13%. The company generates $1.3B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 24.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 3378.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak3378.HK struggles to generate sufficient returns from assets.
Valuation Score
Weak3378.HK trades at a premium to fair value.
Growth Score
Moderate3378.HK shows steady but slowing expansion.
Financial Health Score
Weak3378.HK carries high financial risk with limited liquidity.
Profitability Score
Weak3378.HK struggles to sustain strong margins.
Key Financial Metrics
Is 3378.HK Expensive or Cheap?
P/E Ratio
3378.HK trades at 82.62 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 3378.HK's PEG of 125.62 indicates potential overvaluation.
Price to Book
The market values Hanx Biopharmaceuticals (Wuhan) Co., Ltd. at 10.71 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -4.58 times EBITDA. This is generally considered low.
How Well Does 3378.HK Make Money?
Net Profit Margin
For every $100 in sales, Hanx Biopharmaceuticals (Wuhan) Co., Ltd. keeps $2.99 as profit after all expenses.
Operating Margin
Core operations generate 4.68 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $13.13 in profit for every $100 of shareholder equity.
ROA
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. generates $2.91 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. generates limited operating cash flow of $94.54M, signaling weaker underlying cash strength.
Free Cash Flow
Hanx Biopharmaceuticals (Wuhan) Co., Ltd. produces free cash flow of $94.54M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $0.70 in free cash annually.
FCF Yield
3378.HK converts 61.94% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
82.62
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
125.62
vs 25 benchmark
P/B Ratio
Price to book value ratio
10.71
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.12
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
2.04
vs 25 benchmark
Current Ratio
Current assets to current liabilities
0.69
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.13
vs 25 benchmark
ROA
Return on assets percentage
0.03
vs 25 benchmark
ROCE
Return on capital employed
0.08
vs 25 benchmark
How 3378.HK Stacks Against Its Sector Peers
| Metric | 3378.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 82.62 | 29.15 | Worse (Expensive) |
| ROE | 13.13% | 438.00% | Weak |
| Net Margin | 2.99% | -11409.00% (disorted) | Weak |
| Debt/Equity | 2.04 | 0.78 | Weak (High Leverage) |
| Current Ratio | 0.69 | 5.14 | Weak Liquidity |
| ROA | 2.91% | -21.00% (disorted) | Weak |
3378.HK outperforms its industry in 0 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Hanx Biopharmaceuticals (Wuhan) Co., Ltd.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation